StreetInsider.com News Articles

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Deykin Aaron

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659802.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Deykin Aaron

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659802.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Ambrose Allison

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659804.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Ambrose Allison

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659804.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Houghton Adam

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659807.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Houghton Adam

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659807.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Sutherland Everett Rand

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659808.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: Sutherland Everett Rand

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659808.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: GRAY MICHAEL

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659818.html

Form 4 Upstream Bio, Inc. For: Jun 16 Filed by: GRAY MICHAEL

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659818.html

Upstream Bio drug shows improvements in 80% of nasal polyp patients

Sun, 14 Jun 2026 10:00:18 -0400

Upstream Bio Inc. (NASDAQ: UPB) reported new data from its Phase 2 VIBRANT trial showing that 79% of participants treated with verekitug achieved clinically meaningful improvements in nasal polyp scores compared to 24% in the placebo group. The company presented these findings at the European Academy of Allergy and Clinical Immunology Congress in Istanbul.

The trial evaluated verekitug, administered every three months, in 81 adults with chronic rhinosinusitis with nasal polyps (CRSwNP) over 24 weeks. Verekitug achieved a placebo-adjusted reduction in nasal polyp score of -1.95 at Week 24, nearly double the 1.0 point reduction considered clinically meaningful.

Additional results showed 72%

Upstream Bio drug shows improvements in 80% of nasal polyp patients

Sun, 14 Jun 2026 10:00:18 -0400

Additional results showed 72%

Upstream Bio drug shows improvements in 80% of nasal polyp patients

Sun, 14 Jun 2026 10:00:18 -0400

Additional results showed 72%

Upstream Bio drug shows improvements in 80% of nasal polyp patients

Sun, 14 Jun 2026 10:00:18 -0400

Additional results showed 72%

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

– Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score –

WALTHAM, Mass., June 14, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new responder analyses from the Phase 2 VIBRANT trial of

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E

Sun, 14 Jun 2026 10:00:00 -0400

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

JPMorgan Downgrades Upstream Bio (UPB) to Neutral

Fri, 12 Jun 2026 02:55:50 -0400

JPMorgan analyst Tessa Romero downgraded Upstream Bio (NASDAQ: UPB) from Overweight to Neutral with a price target of $8.00 (from $35.00).

The analyst comments: “We are downgrading UPB shares to Neutral from Overweight. Recall, earlier this year, Upstream reported topline results from the phase 2 VALIANT trial in severe asthma and the phase 2 VIBRANT trial in chronic rhinosinusitis with nasal polyps (CRSwNP) which supported phase 3 development utilizing a high-dose quarterly (Q12W) regimen of verekitug of up to 400mg, administered in a single injection; verekitug is a recombinant human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin receptor (TSLPR).

JPMorgan Downgrades Upstream Bio (UPB) to Neutral

Fri, 12 Jun 2026 02:55:50 -0400

JPMorgan analyst Tessa Romero downgraded Upstream Bio (NASDAQ: UPB) from Overweight to Neutral with a price target of $8.00 (from $35.00).

Form 4 Upstream Bio, Inc. For: Jun 09 Filed by: Chimovits Erez

Thu, 11 Jun 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26637204.html